Dr. Geeta Vemuri promoted to Partner at Quaker BioVentures

From: CityBizList Philadelphia
Read entire press release

... “Geeta has a considerable impact on Quaker’s capabilities, culture, and investments,” says Sherrill Neff, Partner at Quaker BioVentures. “Her expertise and scientific background in biotherapeutics have significantly helped the firm in its ability to source, invest in, and exit promising growth companies. She has played an integral role in our team and funds, and we look forward to Geeta’s continued help in executing Quaker’s investment strategy effectively.”

Dr. Vemuri joined Quaker BioVentures as a Senior Associate in 2003, before being promoted to Vice President, and later Principal. Her extensive experience with early-stage biotherapeutic and healthcare companies has led the firm to a number of investment commitments. She is a former board member of Protez Pharmaceuticals, which was recently sold to Novartis, and is also a current member of the Board of Directors at Argolyn BioSciences, Cellatope, and Immune Control. She is a Board Observer for Optherion, Regado, Tengion, and Tranzyme.

“I have enjoyed being a part of the Quaker team for the past five years, and look forward to continuing to support the growth of the Mid-Atlantic biotechnology industry as a Partner with the firm,” says Dr. Vemuri. “Quaker has a unique investment approach. It is a pleasure to work each day with the firm’s talented investment professionals, as well as so many driven portfolio company leaders.” ...